Spots Global Cancer Trial Database for A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
Official Title: A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT00290550
Conditions
Interventions
Study Description
Brief Summary: This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Medical Monitor
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
